Professor Michael Peter Findlay
Michael Findlay completed his undergraduate studies at the University of Otago. He was awarded his Fellowship of the Royal Australasian College of Physicians in 1990 after training in Wellington and Sydney. His post-Fellowship research in the treatment of gastro-intestinal cancers at the Royal Marsden Hospital in London resulted in the awarding of the degree of Doctor of Medicine in 1995. After appointments at Sydney Cancer Centre and Wellington Cancer Centre between 1994 and 2002, he was appointed as the foundation Professor in Oncology at the University of Auckland. With his appointment he established Cancer Trials New Zealand, a clinical trials coordinating centre engaged in the design and conduct of clinical and translational trials in a wide range of cancer types – trials that are considered to be of particular significance to New Zealanders. Other current activities related to cancer and cancer research include: board director and deputy–chairman of the Australasian Gastro-Intestinal Trials Group and its Scientific Advisory Committee; member of the Genesis Oncology Trust Scientific Evaluation Committee, board member of the Auckland Division of the New Zealand Cancer Society; and member of the National Ethics Advisory Committee. Michael is an advocate of research-driven cancer care.
Selected publications and creative works (Research Outputs)
- Gasser, O., Sharples, K. J., Barrow, C., Williams, G. M., Bauer, E., Wood, C. E., ... Jones, J. (2018). A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. Cancer immunology, immunotherapy : CII, 67 (2), 285-298. 10.1007/s00262-017-2085-9
Other University of Auckland co-authors: Geoffrey Williams, Rod Dunbar, Margaret Brimble
- Muthukaruppan, A., Lasham, A., Blenkiron, C., Woad, K. J., Black, M. A., Knowlton, N., ... Shelling, A. N. (2017). Gene expression profiling of breast tumours from New Zealand patients. The New Zealand medical journal, 130 (1464), 40-56.
Other University of Auckland co-authors: Annette Lasham, Cherie Blenkiron, Andrew Shelling, Cristin Print, Anita Muthukaruppan
- Wasan, H. S., Gibbs, P., Sharma, N. K., Taieb, J., Heinemann, V., Ricke, J., ... Mills, J. (2017). First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A combined analysis of three multicentre, randomised, phase 3 trials. The Lancet Oncology, 18 (9), 1159-1171. 10.1016/S1470-2045(17)30457-6
- Leong, T., Smithers, B. M., Haustermans, K., Michael, M., Gebski, V., Miller, D., ... O’Connell RL (2017). TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 24 (8), 2252-2258. 10.1245/s10434-017-5830-6
- Muthukaruppan, A., Lasham, A., Woad, K. J., Black, M. A., Blenkiron, C., Miller, L. D., ... Shelling, A. N. (2017). Multimodal assessment of estrogen receptor mRNA profiles to quantify estrogen pathway activity in breast tumors. Clinical Breast Cancer, 17 (2), 139-153. 10.1016/j.clbc.2016.09.001
Other University of Auckland co-authors: Andrew Shelling, Cristin Print, Annette Lasham, Cherie Blenkiron, Anita Muthukaruppan
- Lawrence, N., Hinder, V., Murray, M., Macapagal, J., Thompson, P., Sharples, K., & Findlay, M. (2017). Transient elevation in serum carcinoembryonic antigen while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance?. Asia-Pacific journal of clinical oncology, 13 (2), e124-e131. 10.1111/ajco.12402
- Firth, M. J., Sharples, K. J., Hinder, V. A., Macapagal, J., Sarfati, D., Derrett, S. L., ... Lawrenson, R. A. (2016). Methods of a national colorectal cancer cohort study: the PIPER Project. The New Zealand medical journal, 129 (1440), 25-36.
Other University of Auckland co-authors: Andrew Hill, Papaarangi Reid
- van Hazel, G. A., Heinemann, V., Sharma, N. K., Findlay, M. P. N., Ricke, J., Peeters, M., ... Ferguson, T. (2016). SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (plus or minus Bevacizumab) versus mFOLFOX6 (plus or minus Bevacizumab) plus Selective Internal Radiation Therapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 34 (15), 1723-1731. 10.1200/jco.2015.66.1181